抗憂鬱藥的全球市場分析及今後策略

本報告已在2011年07月19日停止出版。

簡介

抗憂鬱藥市場在過去10年間急速地成長，現在的市場規模估計已經擴展到169億美金。但是預計從2009年之後病患會逐漸減少，並且會以負 21.5% 的速度在 2011 縮小至 135 億美金的規模。

專門在醫療、IT、金融服務等產業裡進行調查分析並且提供可靠情報的 Datamonitor（總公司：倫敦），針對抗憂鬱藥市場的動向及今後策略進行調查與分析，並且統整其結果出版了一份名為 "Commercial Insights: Antidepressants - Sliding SSRI Revenues Inevitable"的調查報告書。

此報告書使用95張圖表並以淺顯易懂的方式，針對全球抗憂鬱藥市場的現況及未來動向、今後策略進行詳盡地分析。此報告書的概略架構如下所示。

1.摘要

• 調查範圍
• 市場傾向
• 要點
• 2002年/2003年的主要大事

2.市場分類及定義

• 焦點
• 定義
• 標準的治療
• 相關製藥市場及動向

3.全球市場概要

• 要點
• 全球抗憂鬱劑市場的分析及未來預測
• Serotonergic系列藥品市場的分析
  • 實績
  • 銷售額與銷售量
  • 未來預測
  • 研究開發動向
  • 製品分析：Prozac、Paxil、Zoloft、Celexa、Lexapro
• Noradrenergic系列藥品市場的分析
  • 實績
  • 未來預測
  • 研究開發動向
  • 製品分析：Effexor、Remeron
• 最新混合藥品市場的分析
  • 實績
  • 未來預測
  • 研究開發動向
  • 製品分析：Wellbutrin

4.文件夾及商品壽命管理

• 要點
• 文件夾管理
• 商品壽命管理

5.製品的策略性定位

• 要點
• 製品的目標
• 製藥廠商所扮演的角色
• 對象患者及影響
• 品牌印象
• 價格與賠償
• 全球抗憂鬱劑市場資料
  • 全球整體
  • Serotonergic系列藥品
  • Noradrenergic系列藥品
  • 最新混合藥品

目錄

Introduction

The global antidepressant market has seen extraordinary growth over the last decade. However, with few entrants and a flood of patent expiries by 2009, the dynamics of this $16.9 billion market are set to undergo a major change. As generic competition intensifies, companies need to carefully re-examine their strategies if they wish to protect their market share.

Key findings and highlights

• Antidepressant sales are expected to decrease by -21.5% to $13.5 billion by 2011. During the forecast period 2003-11, the market will experience a period of high volatility as revenues are impacted by consecutive patent expiries and limited product launches.
• The serotonergic class dominates the market, accounting for 57.6% of market share in 2002. However, all of the leading brands will suffer patent expiries by 2009. As physicians are encouraged to utilize cheaper generics, brand players must look towards maximizing revenues through product differentiation and innovative lifecycle strategies.
• Wyeth' s noradrenergic, Effexor has positioned itself as a relatively unique product in the antidepressant market. However, with Lilly' s Cymbalta demonstrating a similar mode of action and anticipated to launch in mid 2004, Effexor is expected to undergo its first major challenge to its market position.

Reasons to buy

• Assess leading antidepressants and identify key success factors within this sector
• Understand key market drivers and predict the future performance of key compounds
• Benchmark pipeline antidepressants against currently marketed products and assess their future market potential

Table of Contents

CHAPTER 1 EXECUTIVE SUMMARY

Scope of the analysis

Datamonitor insight into the antidepressant market

The antidepressant market is set to undergo a period of rapid change as seven out of the eight leading brands suffer US patent expiries by 2008. With only a handful of new products anticipated to replace these blockbuster products, the market is expected to decrease by -21.5% to $13.5 billion by 2011, as physicians are encouraged to utilize cheaper generics. Brand players must look towards maximizing revenues through product differentiation and innovative lifecycle strategies.

Forest' s Lexapro is the only marketed antidepressant expected to achieve a positive CAGR over the full forecast period, 2003–11. Nonetheless, success is reliant on the company' s ability to switch patients from Lexapro' s predecessor, Celexa by convincing physicians of the resulting clinical benefits. The key drivers to initiating this switch are to clearly differentiate the two products and to present Lexapro as a more complete compound.

Wyeth' s noradrenergic, Effexor has positioned itself as a relatively unique product in the antidepressant market. However, with Lilly' s Cymbalta demonstrating a similar mode of action and anticipated to launch in mid 2004, Effexor is expected to undergo its first major challenge to its market position. Effexor must consolidate its position by gaining new indications in areas such as neuropathic pain and moving the focus to primary care.

Summary

Key metrics

Key market events during 2002/2003

Regulators warn about use of antidepressants in pediatrics

Paxil generics launched in the US

Lilly announces expected launch of Cymbalta

CHAPTER 2 MARKET SEGMENTATION & DEFINITION

Strategic scoping and focus

Poor diagnosis and treatment

Concerns over safety

Limited improvements and new chemical entities

Lifecycle strategies

Market definition

The gold standard in major depressive disorder

Associated pharmaceutical markets and indications

Depression and anxiety

Depression and novel non-anxiety indications

CHAPTER 3 GLOBAL MARKET OVERVIEW

Key findings

Global antidepressant market analysis

Global market forecast

Serotonergic class analysis

Serotonergic market performance

Serotonergic value and volume analysis

Serotonergic market forecast

R&D drugs in the serotonergic class

Prozac analysis

Paxil analysis

Zoloft analysis

Celexa analysis

Lexapro analysis

Other recent events in the serotonergic market

Noradrenergic class analysis

Noradrenergic market performance

Noradrenergic market forecast

R&D drugs in the noradrenergic class

Effexor analysis

Remeron analysis

Novel compound class analysis

Novel compound market performance

Novel compound market forecast

R&D drugs in the novel compound class

Wellbutrin analysis

CHAPTER 4 PORTFOLIO AND LIFECYCLE MANAGEMENT

Key findings

Portfolio management

Market attractiveness

Positioning of the major antidepressant players

Portfolio analysis

Lifecycle management of antidepressants

The antidepressant product lifecycle

Launch strategy and market penetration

Optimizing peak sales

Revenue protection strategies

CHAPTER 5 STRATEGIC PRODUCT POSITIONING

Key findings

Physician-focused product positioning

Brand positioning for key products in the major markets

Benchmarks and case studies

Pharmacist role

Patient targeting and influence

Patient sub-group positioning analysis

DTC advertising

Brand imaging

Product specific websites

Company health information websites

Company activity with patient advocacy groups

Patient education initiatives

Pricing and reimbursement

US

EU

Health economic considerations

Pricing strategies

Global antidepressant market data

Serotonergic market data

Noradrenergic market data

Novel compound market data

List of tables

List of figures

Bibliography

Market segmentation and definition

Global market overview

Strategic product positioning

National Formularies

Websites

Report methodology

Date of research completion

About Datamonitor

About Datamonitor Healthcare

Datamonitor Healthcare' s research and analysis methodologies

Datamonitor Healthcare' s therapy area capabilities

About the CNS analysis team

Datamonitor Healthcare' s Consulting expertise

Key therapy team members

Disclaimer

List of Tables

Table 1: Key parameters of the antidepressant market to 2011

Table 2: Forecast for key currently marketed antidepressant products, 2003–11

Table 3: Defining the gold standard: key clinical trial results for fluoxetine

Figure 3: Comparative class contribution to antidepressant market growth by quarter, 2001–02

Figure 4: Global antidepressant market forecast, 2003–11

Table 4: Global antidepressant market forecast, 2003–11

Table 5: Global sales of leading serotonergics ($m), 1997–2002

Figure 5: Relative sales performance of top four serotonergics ($m), 2001–02

Figure 6: Serotonergic value/volume analysis, 2001–02

Figure 7: Serotonergic market concentration, 2003–11

Table 6: Global serotonergic forecast by leading brand, 2003–11

Table 7: R&D included in the serotonergic class forecast, 2003–11

Table 8: Prozac: key facts

Table 9: Key fluoxetine events, 2002–03

Table 10: Paxil: key facts

Table 11: Key paroxetine events, 2003

Table 12: Key paroxetine events, 2002

Table 13: Zoloft: key facts

Table 14: Key sertraline events, 2002–03

Table 15: Celexa: key facts

Table 16: Key citalopram events, 2002–03

Table 17: Lexapro: key facts

Table 18: Key escitalopram events, 2003

Table 19: Key escitalopram events, 2002

Table 20: Serzone: key facts

Table 21: Key nefazodone events, 2002–03

Table 22: Luvox: key facts

Table 23: Key fluvoxamine events, 2002–03

Table 24: Global sales of leading noradrenergics ($m), 1997–2002

Figure 18: Noradrenergic contribution to market growth by quarter, 2001–02

Figure 19: Noradrenergic market concentration, 2003–11

Table 25: Global noradrenergic forecast by leading brand, 2003–11

Table 26: R&D included in the noradrenergic class forecast, 2003–11

Table 27: Effexor: key facts

Table 28: Effexor events, 2002–03

Table 29: Remeron: key facts

Table 30: Mirtazapine events, 2002–03

Table 31: Global sales of leading novel compounds ($m), 1997–2002

Figure 24: Novel compound market concentration, 2003–11

Table 32: Global novel compound forecast by leading brand, 2003–11

Table 33: R&D included in the noradrenergic class forecast, 2003–11

Table 34: Wellbutrin: key facts

Table 35: Key bupropion events, 2002–03

Table 36: Total, CNS and antidepressant performance of the antidepressant market leaders, 2002

Table 37: Growth in total ethical, CNS and antidepressant revenues for the antidepressant market leaders, 2001–02

Table 38: Antidepressant market leader key drug group portfolio composition, 2002

Table 39: Overview of antidepressant pipeline and marketed drugs of key players

Table 40: GSK marketed antidepressant products, 2001–2002

Table 41: Pfizer marketed antidepressant product, 2001–2002

Table 42: Wyeth marketed antidepressant product, 2001–2002

Table 43: Forest marketed antidepressant products, 2001–2002

Table 44: Lundbeck' s marketed antidepressant products, 2001–2002

Table 45: Organon' s marketed antidepressant product, 2001–2002

Table 46: Lilly marketed antidepressant product, 2001–2002

Table 47: BMS' s marketed antidepressant products, 2001–2002

Table 48: Solvay' s marketed antidepressant products, 2001–2002

Table 49: Key themes pursued by major antidepressant companies at main psychiatric conferences, 2003

Table 50: Selected market pricing data for antidepressants, 2003

Table 51: Global sales in the antidepressant market by drug class, 2001–02

Table 52: Serotonergic fact file

Table 53: Global sales of the leading branded serotonergic drugs, 2001–02

Table 54: Noradrenergic fact file

Table 55: Global sales of the leading branded noradrenergic drugs, 2001–02

Table 56: Novel compound fact file

Table 57: Global sales of the leading branded novel compound drugs, 2001–02

List of Figures

Figure 1: Key drivers of the antidepressant market to 2011

Figure 2: Development of the antidepressant drug classes and leading drugs within each class , 1950–2003.

Figure 8: SWOT analysis for Prozac

Figure 9: Global sales forecasts for Prozac, 2003–11

Figure 10: SWOT analysis for Paxil

Figure 11: Global sales forecasts for Paxil, 2003–11

Figure 12: SWOT analysis for Zoloft

Figure 13: Global sales forecasts for Zoloft, 2003–11

Figure 14: SWOT analysis for Celexa

Figure 15: Global sales forecasts for Celexa, 2003–11

Figure 16: SWOT analysis for Lexapro

Figure 17: Global sales forecasts for Lexapro, 2003–11

Figure 20: SWOT analysis for Effexor

Figure 21: Global sales forecasts for Effexor, 2003–11

Figure 22: SWOT analysis for Remeron

Figure 23: Global sales forecasts for Remeron, 2003–11

Figure 25: SWOT analysis for Wellbutrin

Figure 26: Global sales forecasts for Wellbutrin, 2003–11

Figure 27: Competitive attractiveness of the antidepressant market, 2002–11

Figure 28: Comparative attractiveness of the serotonergic class versus noradrenergic class, 2002–11

Figure 29: Positioning of the antidepressant market leader portfolios, 2001–02

Figure 30: Global sales of Prozac, 1992–2002

Figure 31: MDD diagnosing medical professional, 2002

Figure 32: Effexor website information for health care professionals

Figure 33: Prozac patient product positioning

Figure 34: Paxil website

Figure 35: Pfizer' s health information website

Figure 36: National Phobics Society website, sponsored by GSK

Figure 37: Datamonitor' s Healthcare Consultancy

Figure 38: Datamonitor Healthcare' s Therapeutic Consulting capabilities

相關商品

精神病相關市場調查報告書

阿茲海默症：新藥・市場・企業
Alzheimer disease - new drugs, markets and companies
價格 : US $ 3500
出版日期 : 2012年04月

精神醫學相關的各種合作契約：契約條件・合意內容
Psychiatry Partnering Terms and Agreements
價格 : US $ 2695
出版日期 : 2012年03月

R&D趨勢:憂鬱症 - 成熟市場下逐漸減少的治療藥物
R&D Trends: Depression - Clinical attrition driven by mature market conditions
價格 : US $ 3800
出版日期 : 2012年01月

Datamonitor發行的製藥相關市場調查報告書

美國及EU主要5個國家的HIV藥市場:市場預測

HIV Market Forecast

價格 : US $ 11400

出版日期 : 2012年02月

市場及產品預測:HIV - 患病人口的擴大與新STR劇增的歐美銷售

Market and Product Forecasts: HIV - Rising prevalence and novel STRs boost sales in the US and Europe

價格 : US $ 11400

出版日期 : 2012年02月

FDA的Bydureon的認證:醫生的見解

Bydureon FDA Approval: Physician Opinion

價格 : US $ 3800

出版日期 : 2012年02月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!